ImmuPharma PLC is headquartered in London and has its research operations in France (ImmuPharma (France) SA) and Switzerland (ImmuPharma AG). ImmuPharma is dedicated to the development of innovative drugs to treat serious medical conditions, characterised by
High unmet medical need
Low marketing costs
Relatively low development costs
Founded first in Basel, Switzerland in 1999 and led by an experienced management team, ImmuPharma now has important R&D collaboration arrangements with highly respected health and medical research laboratories in Europe. The company plans either to bring its drug candidates to market itself, or to license them in corporate deals to other pharmaceutical companies.
Developer of a promising treatment called Lupuzor, for the autoimmune disease lupus
Signed a licensing deal with a US firm worth US$95mln in milestone payments and carried costs
Successful completion of a phase III trial should pave the way for commercialisation